Epidemiology of primary brain and other Central nervous system tumors for practicing healthcare providers in neuro-oncology, CBTRUS 2018-20222022
Authors:
- Michal NisnboymMNMichal Nisnboym
- Mackenzie PriceMPMackenzie Price
- Julia R BenedettiJBJulia R Benedetti
- Daniel B LandiDLDaniel B Landi
- Katherine B PetersKPKatherine B Peters
- Daniel J BratDBDaniel J Brat
- Tarik TihanTTTarik Tihan
- Carol KruchkoCKCarol Kruchko
- Jill S Barnholtz-SloanJBJill S Barnholtz-Sloan
- Quinn T OstromQOQuinn T Ostrom
- 3 July 2026
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Practice
Abstract
Background: The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-based data for primary brain and other central nervous system tumors (BTs) in the United States. Summarized are the key findings from the 2025 CBTRUS annual statistical report and additional clinically relevant statistics for neuro-oncology healthcare providers. Methods: CBTRUS incidence data are an aggregation of 48 central cancer registries (CCRs) from the CDC’s National Program of Cancer Registries (NPCR) and four CCRs from the NCI’s Surveillance, Epidemiology, and End Results Program covering the entire US population. Puerto Rico was excluded. Survival data were obtained from 43 NPCR CCRs. Mortality data were obtained from the National Vital Statistics System. All incidence and mortality rates were age-adjusted using the 2000 US standard population. Relative survival was estimated using the life table method. Overall survival was estimated using Kaplan–Meier models. Results: The average annual age-adjusted incidence rate (AAAIR) of all BTs was 26.05 per 100,000 population. Incidence was higher among females and non-Hispanic Black individuals. The most common malignant tumors were gliomas. The most common non-malignant tumors were low-grade meningiomas. Mortality rates and median survival varied by age, sex, and tumor type. Conclusions: This summary describes the most up-to-date population-based incidence, mortality, and survival of primary BT types in the United States with an age-focused analysis and aims to serve as a concise resource for neuro-oncology healthcare providers.Keywords
Funding Information
- Centers for Disease Control and Prevention (75D30123P17556)
This publication has 21 references indexed in Scilit:
- Grade-stratified meningioma risk among individuals who are non-Hispanic Black and interactions with male sexJNCI: Journal of the National Cancer Institute, 2024
- National-level overall survival patterns for molecularly-defined diffuse glioma types in the United StatesNeuro-Oncology, 2022
- Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationGenetics in Medicine, 2022
- Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United StatesNeuro-Oncology, 2022
- Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECTJournal of Neuro-Oncology, 2019
- Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based studyJournal of Neuro-Oncology, 2017
- Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid TumorsCancer Cell, 2016
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- Epidemiology and etiology of meningiomaJournal of Neuro-Oncology, 2010
- Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspectiveActa Neuropathologica, 2010